Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118423) titled 'Prognostic Value of the Ubiquitin-Proteasome System and RACK1 Expression in Lung Adenocarcinoma' on Feb. 5.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Shanghai East Hospital
Condition:
lung adenocarcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-05
Target Sample Size: Observation group:120;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=301288
Disclaimer: Curated by HT Syndication....